A Controlled Study of Steroids Plus Cyclosporin Therapy for Patients of

Status Recruiting

Clinical Trial Summary

This prospective, randomized, controlled, multicenter clinical trial will evaluate Opportunity, Validity and Security of Steroids Plus Cyclosporin therapy for patients of Idiopathic Membranous Nephropathy.

Clinical Trial Description

Idiopathic membranous nephropathy is a main reason for nephropathy. Since it can get spontaneous remission, in KDIGO, it is recommend that initial therapy should be started only in patients with nephrotic syndrome and when at least the following condition is met:urinary protein excretion persistently exceeds 4g/d and remains at over 50% of the baseline value,and does not show progressive and antiproteinuric therapy during an observation period of at least 6 months. But many retrospective researches reported that using steroids and immunosuppressive agents were better than waiting for spontaneous remission. There were few prospective, randomized, controlled research on whether it is better that begin to use steroids and immunosuppressive agent early without waiting for 6 months. In our study,we evaluate the validity and security of steroids plus cyclosporin therapy in idiopathic membranous nephropathy. This will be a prospective, randomized, controlled, multicenter study. Patients in treatment group will receive oral methylprednisolone 0.4mg/kg/d and 3.5~5mg/kg/d cyclosporin for 6 months. Patients in control group will waiting for spontaneous remission for 6 months,if there were no spontaneous remissions, patients in control group will receive oral methylprednisolone 0.4mg/kg/d and 3.5~5mg/kg/d cyclosporin for 6 months. After followed-up for 6 months the curative and side effect of steroid plus cyclosporin therapy in the early stage of idiopathic membranous nephropathy will be evaluated. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02173106
Study type	Interventional
Source	Sun Yat-sen University
Contact	Zongpei Jiang, MD&Ph D
Phone	8620-38379727
Email	jx.home@medmail.com.cn
Status	Recruiting
Phase	Phase 2
Start date	June 2014
Completion date	December 2016

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03510286` - Validation of a PrCr Dipstick Diagnostic Test in Ghana
Completed	`NCT05086549` - An Observation Study to Evaluate the Renoprotective Effect of Fimasartan in Patients With DKD and Proteinuria
Terminated	`NCT04051957` - Isosorbide Mononitrate For Anti-Vascular Endothelial Growth Factor (VEGF) Induced Kidney Injury	Phase 2
Terminated	`NCT02057523` - Acthar as Rescue Therapy for Transplant Glomerulopathy in Kidney Transplant Recipients	Phase 4
Completed	`NCT02226055` - An Investigation Into the Cardiovascular Risk and Aetiology of CKDu in Sri Lanka	N/A
Completed	`NCT02232763` - Efficacy and Safety of Losartan in Pediatric Chronic Kidney Disease With Tubular Proteinuria	Phase 3
Completed	`NCT00493727` - Use of Mucomyst to Ameliorate Oxidant Stress in Diabetics With Proteinuria	N/A
Active, not recruiting	`NCT00565396` - Effectiveness Study on Fosinopril and/or Losartan in Patients With Chronic Kidney Disease Stage 3	N/A
Recruiting	`NCT05759754` - Effects of Traditional Chinese Medicine (GSJYF) in Children With Inherited Proteinuric Kidney Disease	N/A
Withdrawn	`NCT02882373` - Arginine in Treating Patients With Anti-VEGF Induced Kidney Injury	Phase 2
Completed	`NCT02327403` - Belatacept Conversion in Proteinuric Kidney Transplant Recipients	Phase 2
Recruiting	`NCT01773382` - The Effects of Weight Reduction in IgA Nephropathy	N/A
Completed	`NCT00915200` - N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy	Phase 2
Completed	`NCT01029002` - The Effects of Vitamin D Repletion in Vitamin D Deficient Patients With Stage 3 and 4 Chronic Kidney Disease	Phase 3
Withdrawn	`NCT00541619` - Sympathetic Overactivity in Essential Hypertension	N/A
Withdrawn	`NCT00392132` - Impact of Screening Patients With HIV for Kidney Disease
Terminated	`NCT00001978` - Determination of Kidney Function
Recruiting	`NCT05457283` - A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria	Phase 3
Completed	`NCT04874753` - The Effect of COVID-19 Pandemia on Follow up of Patients With Chronic Kidney Disease
Recruiting	`NCT02972346` - Availability Study of ACTH to Treat Children SRNS/SDNS	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

A Controlled Study of Steroids Plus Cyclosporin Therapy for Patients of Idiopathic Membranous Nephropathy

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms